NCT04863638

A Immuno-bridging and Immunization Schedules Study of COVID-19 Vaccine (Vero Cell), Inactivated

A Immunobridging and Immunization Schedules Study of COVID-19 Vaccine (Vero Cell), Inactivated in Population Aged ≥ 60 Years Old and 3-17 Years Old Compared With That in Population Aged 18-59 Years Old

• Status: Unknown
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 4,400 (actual)
• Sponsor: China National Biotec Group Company Limited · Industry
• Sex: All
• Age: 3 Years
• Healthy volunteers: Accepted

Summary

This trial is a randomized study to evaluate the immunogenicity of COVID-19 Vaccine (Vero Cell), Inactivated and in population aged 60 years old and 3-17 years old with different schedules compared to that in population aged 18-59 years old with 2-dose schedule. And subjects in the same age are randomly assigned to different immunization schedule groups.

Detailed description

This trial is a randomized study to evaluate the immunogenicity of COVID-19 Vaccine (Vero Cell), Inactivated and in population aged 60 years old and 3-17 years old with different schedules (D0,21,42, D0, 21,111,or D0,21,171)compared to that in population aged 18-59 years old with 2-dose schedule (D0,21). And subjects in the same age are randomly assigned to different immunization schedule groups.

Conditions

• Covid19

Interventions

Type	Name	Description
BIOLOGICAL	3-doses schedule 1 of COVID-19 Vaccine (Vero Cell), Inactivated	the schedule of Day 0, 21, 42
BIOLOGICAL	3-doses schedule 2 of COVID-19 Vaccine (Vero Cell), Inactivated	the schedule of Day 0, 21, 111
BIOLOGICAL	3-doses schedule 3 of COVID-19 Vaccine (Vero Cell), Inactivated	the schedule of Day 0, 21, 171
BIOLOGICAL	2 doses of vaccine	the schedule of Day 0, 21

Timeline

• Start date: 2021-04-29
• Primary completion: 2021-12-20
• Completion: 2024-03-31
• First posted: 2021-04-28
• Last updated: 2023-06-18

Locations

1 site across 1 country: China